Clinical Trials
30 trialsPembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer
Samsung Medical Center
Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Northwestern University
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Memorial Sloan Kettering Cancer Center
RAMIRIS
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
National Health Research Institutes, Taiwan
TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases
City of Hope Medical Center
SEQUEL
Hoosier Cancer Research Network
Predicting the Efficacy in Advanced Gastric Cancer.
City of Hope Medical Center
T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Yonsei University
Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer
City of Hope Medical Center
PLATFORM
Royal Marsden NHS Foundation Trust
Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
Hoosier Cancer Research Network
Real-world Data of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Advanced Gastric Cancer
Hellenic Cooperative Oncology Group
A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis
The First Affiliated Hospital with Nanjing Medical University
RAMTAS
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
SOCRATE
Federation Francophone de Cancerologie Digestive
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Academic and Community Cancer Research United
Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer
Xijing Hospital
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
RiME
University of Kansas Medical Center
RAMOS
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
RAMSES/FLOT7
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer
SCRI Development Innovations, LLC
ARMANI
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Real-world Data (RWD) of Ramucirumab Plus Paclitaxel
Hallym University Medical Center
Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)
Yonsei University
MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
University of Southern California
Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer
Memorial Sloan Kettering Cancer Center
AIO-STO-0218
Charite University, Berlin, Germany